ALFA Finder| Revenue growth | Total income +26% YoY Q2; +24% H1 |
|---|---|
| Margins | Q2 EBITDA margin 36.7% vs 31.7% YoY; Q1 36.0% |
| Demand visibility | Patients 0.42 Mn (+11% YoY); tests 2.40 Mn (+9%) |
| Management confidence | CEO confident in H2 FY27 growth trajectory |
Growth
Q2 total income +26% YoY, EBITDA +45%, PAT +69%; H1 PAT +54%.
Outlook
Upcoming 4 hubs and 7 spokes in FY27. No explicit numeric growth guidance given.
Risks
Newer centres (<2 yrs) margin only 11.8%. Ind AS 116 lifts EBITDA (IGAAP Q2 margin 29.2% vs 36.7%).
Last quarter's promises, checked
Delivered
- Guided EBITDA margin not below 34% for FY27 → Q2 36.7% (Q1 36.0%) (= BEAT)
- Guided genomics ~20% quarterly growth → Q2 INR 14.6 Mn, +115% YoY (= BEAT)
- Guided <2yr centres to strengthen from 6.5% margin → Q2 11.8% (= BEAT)
Partly delivered
- Guided 4 hubs + 7 spokes FY27 → H1 3 hubs + 6 spokes opened (= PARTIAL)
- Guided FY27 capex Rs 70-80 cr → H1 INR 336 Mn (= PARTIAL, FY pending)
Investor Presentation filed with BSE, NSE: SURAKSHA. Summary written with AI assistance from the document.
Suraksha Diagnostic Ltd: key numbers
- Share price
- ₹340.50
- Market cap
- ₹1,773 Cr
- Revenue (annual)
- ₹310.4 Cr
- Net profit (annual)
- ₹32.19 Cr
- P/E (TTM)
- 42.4×Sector 54.7×
- Promoter holding
- 49.10%+0.00% QoQ
- FII holding
- 13.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suraksha Diagnostic Ltd
All →Suraksha Diagnostic Earnings Call Transcript: Key Takeaways
Suraksha delivered strong high double-digit growth in Q2 FY27, crossing the ₹100 crore revenue milestone. Expansion beyond West Bengal is progressing well, though seasonal festive dips are expected in Q3.
- Call
- Guides 18% growth
Suraksha Diagnostic Results Correction
Suraksha Diagnostic corrected operational metrics in its 10 November 2026 results press release. Test volumes and revenue per test were revised; financial figures are unchanged.
Suraksha Diagnostic Results Update
Suraksha Diagnostic reported H1 FY27 total income of ₹1,893.09 million and PAT of ₹277.96 million, up 54% year-on-year. The press release accompanies its unaudited quarterly results.
Suraksha Diagnostic Q2 FY27 Results: Net Profit ₹15 Cr, Up 70.5% YoY
Suraksha Diagnostic Ltd reported revenue from operations of ₹99.1 Cr (+25.9% YoY) and net profit of ₹15 Cr (+70.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹15 Cr · +70.5% YoY
Suraksha Diagnostic Board Meeting Date
Suraksha Diagnostic will hold a board meeting on 10 November 2026 to consider September quarter results and other business. Trading window closes from 1 October to 12 November 2026.
Suraksha Diagnostic Other Announcement
Suraksha Diagnostic notified that RTA KFin Technologies is moving its corporate office to Kokapet, Hyderabad from 1 December 2026, with the registered office unchanged. The change is administrative and affects only the RTA's correspondence address.